Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies

  title={Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies},
  author={Mark W. J. Ferguson and Jonathan A L Duncan and Jeremy S. Bond and James A Bush and Piyush Durani and Karen So and Lisa D. Taylor and Jonquille Chantrey and Tracey Mason and Gaynor James and Hugh G. Laverty and Nicholas L Occleston and Abdul Sattar and Anna Ludlow and Sharon O'Kane},
  journal={The Lancet},
Scar-Improving Efficacy of Avotermin Administered into the Wound Margins of Skin Incisions as Evaluated by a Randomized, Double-Blind, Placebo-Controlled, Phase II Clinical Trial
It is confirmed that avotermin is the first of a new class of regenerative medicines that reduce scarring when administered once or twice to the approximated margins of acute skin incisions.
Avotermin for Scar Improvement following Scar Revision Surgery: A Randomized, Double-Blind, Within-Patient, Placebo-Controlled, Phase II Clinical Trial
Avotermin administration following scar revision surgery is well tolerated and significantly improves scar appearance compared with placebo, and collagen organization in avotermin-treated scars more closely resembled normal skin in 14 of 19 cases.
The evolving role of avotermin in scar prevention
Avotermin is a novel human recombinant TGF-β3 protein that has been studied both in vitro and in vivo for its antiscarring properties and is evaluated in a recently published Phase II clinical trial.
Safety and Efficacy of a Scar Cream Consisting of Highly Selective Growth Factors Within a Silicone Cream Matrix: A Double-Blinded, Randomized, Multicenter Study
SKN2017B consists of highly selective growth factors within a silicone cream matrix and is well tolerated and effective for surgical scar management.
Avotermin for the improvement of scar appearance: a new pharmaceutical in a new therapeutic area
These studies have shown that prophylactic scar improvement is pharmaceutically achievable and it is anticipated that therapeutics such as avotermin, with a sound mechanistic basis and proof of effectiveness in suitably robust clinical trials, will be available to meet the needs of patients in the foreseeable future.
Therapies with Emerging Evidence of Efficacy: Avotermin for the Improvement of Scarring
The scar improving efficacy of avotermin is confirmed which produces macroscopic and histological improvements in scar architecture, with improved restitution of the epidermis and an organisation of dermal extracellular matrix that more closely resembles normal skin.
Efficacy and Tolerability of a New Pharmaceutical Form of Betamethasone Valerate in the Prevention of Hypertrophic Scars following Anterior Trunk Plastic Surgery: A Preliminary Exploratory Study
The efficacy and tolerability of BMV plaster in the prevention of hypertrophic scar development is promising and shows a significantly greater and more rapid improvement as compared with the non-treated wounds after 4 and 8 weeks of treatment.
A Controlled Clinical Trial With Pirfenidone in the Treatment of Pathological Skin Scarring Caused by Burns in Pediatric Patients
Topical administration of 8% pirfenidone gel 3 times a day is more effective and safe in the treatment of hypertrophic scars caused by burns in children, as compared with standard pressure therapy.
Antiscarring pharmaceuticals: Lost in translation?
  • M. Ågren, P. Danielsen
  • Medicine
    Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
  • 2014
An excellent randomized, double-blind, exploratory trial on the effect of the putative antiscarring cytokine interleukin-10 (rhIL-10; Prevascar) but the results could not be reproduced in a cohort of scarprone dark-skinned individuals in the present study.


Scar Redness in Humans: How Long Does It Persist after Incisional and Excisional Wounding?
The authors advocate the use of the term “rubor perseverans” to describe the physiologic redness of a normal scar as it matures beyond the first month, a process that does not involve inflammation.
Emerging new drugs for scar reduction
The future market for scar therapy remains highly promising, and researchers are attempting to modify collagen-synthetic and -degradative pathways for potential therapeutic use in scar management.
Neutralising antibody to TGF-beta 1,2 reduces cutaneous scarring in adult rodents.
A novel therapeutic approach to reducing scarring in post-natal life is suggested by using neutralising antibody to transforming growth factor-beta 1,2 to alter the growth factor profile of cutaneous wounds in adult rodents and studying the effect on scar tissue formation.
Scar-free healing: from embryonic mechanisms to adult therapeutic intervention.
  • M. Ferguson, S. O'Kane
  • Medicine, Biology
    Philosophical transactions of the Royal Society of London. Series B, Biological sciences
  • 2004
Scar-improving drugs could have widespread benefits and prevent complications in several tissues, e.g. prevention of blindness after scarring due to eye injury, facilitation of neuronal reconnections in the central and peripheral nervous system by the elimination of glial scarring, restitution of normal gut and reproductive function by prevents strictures and adhesions after injury to the gastrointestinal or reproductive systems, and restoration of locomotor function by preventing scarring in tendons and ligaments.
[International clinical recommendations on scar management].
A qualitative overview of the available clinical literature by an international panel of experts using standard methods of appraisal highlights a primary role for silicon gel sheeting and intralesional corticosteroids in the management of a wide variety of abnormal scars.
The effects of ageing on cutaneous wound healing in mammals.
The absence of a critical review on the effects of advancing age on wound healing has conspired to permit the perpetuation of the belief that well defined tenets exist and to highlight the need for well designed research into an increasingly important field.
Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring.
This study clearly demonstrates isoform specific differences in the role of T GF-betas in wound healing and cutaneous scarring and suggests a novel therapeutic use of exogenous recombinant, TGF-beta 3 as an anti-scarring agent.
Cutaneous wound healing.
The primary goals of the treatment of wounds are rapid wound closure and a functional and aesthetically satisfactory scar.